Information Provided By: 
Fly News Breaks for August 2, 2016
HRTX, PCRX
Aug 2, 2016 | 06:50 EDT
Piper Jaffray analyst David Amsellem sees "significant FDA risk" for Heron Therapeutics' (HRTX) injectable for post-operative pain HTX-011 even though the product showed clear efficacy in two Phase II studies. The 4% incidence of bradycardia across the studies, versus 1% for placebo, gives the analyst pause. Amsellem does not view HTX-011 as a threat to Pacira Pharmaceuticals' (PRTX) Exparel. He reiterates an Overweight rating on Pacira with an $81 price target.
News For PCRX;HRTX From the Last 2 Days
